Health TrialsbyHealthPanel

Edaravone in the Treatment of Optic Neuritis

ConditionOptic Neuritis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorFirst Affiliated Hospital of Guangxi Medical University

About this trial

Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis

Patients with a first episode of optic neuritis in either eye

First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone

Disqualifiers

Myopia over 6 diopters

Refractive media opacity affecting assessment of retinal layers and/or visual acuity

Trial design

Design model

Single group

Treatments tested in this trial

  • Edaravone

    Drug

    Edaravone injection 30mg three times a day

Treatment groups

50 Participants
are divided into 1 treatment group
Group A: EdaravoneExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Best-corrected visual acuity

Best-corrected visual acuity will be measured by "Illiterate E"chart.

Time frame
18 months

Secondary outcomes

1

Ganglion cell-inner plexiform layer

Ganglion cell-inner plexiform layer will be measured by optical coherence tomography.

Time frame
18 months
2

Peripapillary retinal nerve fiber layer

Peripapillary retinal nerve fiber layer will be measured by optical coherence tomography.

Time frame
18 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

First Affiliated Hospital of Guangxi Medical University

Lead sponsor

Source ClinicalTrials.gov
Apply now